Source / episode info
- **Episode:**411
- **Title:**Divine Intervention Episode 411: The Clutch Sarcoidosis Podcast
- **Published:**2022-08-18
- Source:Episode page
One-liner
Sarcoidosis is a prototypical multi-system inflammatory disorder characterized by non-caseating granulomas, affecting the lungs (causing restrictive lung disease), skin (e.g., erythema nodosum), and other organs, with management guided by symptom severity and prognosis prediction via syndromes like Löfgren syndrome.
High-yield summary
- Pathology: Sarcoidosis involves non-caseating granulomas composed of epithelioid macrophages and giant cells; the presence of these macrophages is key to understanding systemic complications.
- Löfgren Syndrome: This triad (bilateral hilar lymphadenopathy, erythema nodosum, arthritis) is highly suggestive of sarcoidosis and predicts a good prognosis.
- Pulmonary Manifestations: Sarcoidosis typically causes interstitial lung disease leading to a restrictive pattern of lung disease (decreased compliance, increased elastance, reduced volumes).
- Hypercalcemia Mechanism: Macrophages within the granulomas overproduce 1-alpha hydroxylase, leading to excessive conversion of Vitamin D to active calcitriol ({1,25-(OH)}_2{D}), causing hypercalcemia.
- Treatment Strategy: Mild/asymptomatic disease requires no treatment; symptomatic disease is treated first with Corticosteroids, followed by agents like Methotrexate or Pyrazinamide if steroids fail.
- Skin Management: For dermatological manifestations, Hydroxychloroquine is the preferred agent (but monitor for retinal toxicity).
Learning objectives
- Identify the characteristic pathological finding of sarcoidosis (non-caseating granulomas).
- Recognize and interpret the clinical significance of Löfgren syndrome.
- Explain the pathophysiology linking macrophage activity to hypercalcemia in sarcoidosis.
- Differentiate between the pulmonary physiological changes seen in restrictive lung disease vs. obstructive disease.
- Select appropriate first-line and second-line agents for symptomatic sarcoidosis, while noting key toxicities.